Novo Nordisk has purchased licensing rights for yet another potential drug for the treatment of severe obesity and diabetes. (Archive photo). Photo: Mads Claus Rasmussen/Ritzau Scanpix
Novo invests in new Chinese weight loss drug
Novo Nordisk has entered into a licensing agreement with United Laboratories of China for a potential new weight loss drug that can also treat diabetes and other diseases. Novo has paid $200 million (approximately 1.4 billion Danish kroner) for the rights to develop, manufacture, and market the...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?